Presenting at these prestigious events is likely to generate positive attention towards Travere Therapeutics and FILSPARI, potentially boosting investor confidence and the stock price in the short term. The focus on a specific treatment for a chronic condition like IgA Nephropathy underlines the company's commitment to addressing unmet medical needs, which could positively influence its market perception.